A5028363097- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- RNA modifications and cancer
- Cancer Cells and Metastasis
- Sarcoma Diagnosis and Treatment
- Neonatal Respiratory Health Research
- Radiomics and Machine Learning in Medical Imaging
- Brain Metastases and Treatment
- Management of metastatic bone disease
- Head and Neck Cancer Studies
- Neuroblastoma Research and Treatments
- Cancer Immunotherapy and Biomarkers
- Drug Transport and Resistance Mechanisms
- Pulmonary Hypertension Research and Treatments
- Lung Cancer Research Studies
- Infant Nutrition and Health
- Cancer, Stress, Anesthesia, and Immune Response
- Genomics and Phylogenetic Studies
- Advanced Radiotherapy Techniques
- Cancer-related cognitive impairment studies
- Genetic factors in colorectal cancer
- Viral-associated cancers and disorders
- Polyomavirus and related diseases
- Cholesterol and Lipid Metabolism
Washington University in St. Louis
2024
Stanford University
2017-2024
Cancer Institute (WIA)
2017-2024
University of California, Irvine
2021-2022
UC Irvine Health
2019-2021
Stanford Cancer Institute
2017-2020
Cancer Prevention Institute of California
2017-2018
University of California, Los Angeles
2016-2017
Identifying molecular residual disease (MRD) after treatment of localized lung cancer could facilitate early intervention and personalization adjuvant therapies. Here, we apply personalized profiling by deep sequencing (CAPP-seq) circulating tumor DNA (ctDNA) analysis to 255 samples from 40 patients treated with curative intent for stage I-III 54 healthy adults. In 94% evaluable experiencing recurrence, ctDNA was detectable in the first posttreatment blood sample, indicating reliable...
Idiopathic pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by accumulation of surfactant. Surfactant synthesis and secretion are restricted to epithelial type 2 (T2) pneumocytes (also called T2 cells). Clearance surfactant dependent upon cells macrophages. ABCG1 highly expressed in both ABCG1-deficient mice accumulate surfactant, lamellar body-loaded cells, lipid-loaded macrophages, B-1 lymphocytes, immunoglobulins, clearly demonstrating that has critical role...
Abstract Background Few studies have addressed the efficacy of palliative radiotherapy (RT) for pediatric osteosarcoma (OS), a disease generally considered to be radioresistant. We describe symptom relief, local control, and toxicity associated with RT among children OS. Procedure Patients diagnosed OS at age 18 under treated palliation symptomatic metastases or recurrence primary site from 1997 2017 were included. retrospectively reviewed details RT, improvement, survival, toxicity. Results...
Abstract Cerebrospinal fluid tumor-derived DNA (CSF-tDNA) analysis is a promising approach for monitoring the neoplastic processes of central nervous system. We applied lung cancer-specific sequencing panel (CAPP-Seq) to 81 CSF, blood, and tissue samples from 24 cancer patients who underwent lumbar puncture (LP) suspected leptomeningeal disease (LMD). A subset cohort ( N = 12) participated in prospective trial osimertinib refractory LMD which serial LPs were performed before during...
Radiotherapy, surgery and the chemotherapeutic agent temozolomide (TMZ) are frontline treatments for glioblastoma multiforme (GBM). However beneficial, GBM nevertheless cause anxiety or depression in nearly 50% of patients. To further understand basis these neurological complications, we investigated effects combined radiotherapy TMZ chemotherapy (combined treatment) on impairments using a mouse model. Five weeks after treatment, mice displayed anxiety-like behaviors, at 15 both anxiety-...
8519 Background: Identifying localized non-small cell lung cancer (NSCLC) patients with residual disease following curative intent therapy is difficult due to normal tissue changes caused by surgery or radiation and an inability detect microscopic disease. Analysis of circulating tumor DNA (ctDNA) might enable identification molecular (MRD) personalization adjuvant treatment approaches but has not been explored in cancer. Methods: We applied CAPP-Seq, ultra-sensitive next-generation...
Classic Hodgkin lymphoma post-transplant lymphoproliferative disorder (HL-PTLD) has been rarely reported in children, with limited data available to guide treatment decisions. We report a retrospective review of five children diagnosed classic HL-PTLD following solid organ transplant between 2007 and 2013 at Stanford University. Patients were treated V chemotherapy involved field radiation therapy. With median follow-up 7.2 years (range, 4.7-10.5 years) since diagnosis, all patients remain...
Abstract Introduction Cerebrospinal fluid tumor-derived DNA (CSF-tDNA) analysis is a promising approach for monitoring neoplastic processes of the central nervous system. We hypothesize that CSF-tDNA in patients with advanced lung cancer improves sensitivity leptomeningeal disease (LMD) diagnosis and enables system response monitoring. Methods applied CAPP-Seq using cancer-specific sequencing panel to 81 CSF, blood, tissue samples from 24 who underwent lumbar puncture (LP) suspected LMD. A...
Cardiovascular disease (CVD) is the leading cause of death in United States, and patients with pulmonary are at least 2-fold more likely to develop cardiovascular complications. Whole-body cholesterol balance a complex tightly regulated process. The sterol-transporter ATP Binding Cassette transporter G1 (ABCG1) critical for maintaining normal cellular lipid homeostasis. After liver intestine, lung 3rd most active lipid-secreting organ. Pulmonary alveolar proteinosis (PAP) rare characterized...
<p>Supplemental Tables S1-S12</p>
<p>Figures S1-S10</p>
<p>Supplemental methods</p>
<p>Supplemental methods</p>
<p>Figures S1-S10</p>
<p>Supplemental Tables S1-S12</p>
<div>Abstract<p>Identifying molecular residual disease (MRD) after treatment of localized lung cancer could facilitate early intervention and personalization adjuvant therapies. Here, we apply personalized profiling by deep sequencing (CAPP-seq) circulating tumor DNA (ctDNA) analysis to 255 samples from 40 patients treated with curative intent for stage I–III 54 healthy adults. In 94% evaluable experiencing recurrence, ctDNA was detectable in the first posttreatment blood sample,...
<div>Abstract<p>Identifying molecular residual disease (MRD) after treatment of localized lung cancer could facilitate early intervention and personalization adjuvant therapies. Here, we apply personalized profiling by deep sequencing (CAPP-seq) circulating tumor DNA (ctDNA) analysis to 255 samples from 40 patients treated with curative intent for stage I–III 54 healthy adults. In 94% evaluable experiencing recurrence, ctDNA was detectable in the first posttreatment blood sample,...